Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
about
Functionally defective germline variants of sialic acid acetylesterase in autoimmunityGenetic and epigenetic alterations in pancreatic carcinogenesisThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPSystemic therapies for pancreatic cancer--the role of pharmacogeneticsSignaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junctionDrosophila cbl is essential for control of cell death and cell differentiation during eye developmentCorrelations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancerPancreatic cancer.Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis.Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesLigand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesisGenetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population.A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junctionEGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.A growing family: adding mutated Erbb4 as a novel cancer targetHigh EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialInsights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of actionEpidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinomaCheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerHER family inhibitors in pancreatic cancer: current status and future directions.Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.Emerging drugs for the treatment of pancreatic cancer.Molecular targeted therapies for pancreatic cancer.Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Epidermal growth factor receptor in pancreatic cancer.The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.Somatic pharmacogenomics in cancer.The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.ErbB receptors in the biology and pathology of the aerodigestive tract
P2860
Q24322817-DB2858A5-8127-49FD-B9A2-A8B391EBEB72Q24598655-EE69F482-A654-4960-A3C7-789DAB38BFAFQ24649549-53EA0C09-608A-4B6D-AEC3-BFB8A9C5A236Q27021716-5E19DBEB-8948-42C8-A450-55CB4A17F3DAQ27026253-C27B8759-8333-415A-826D-7E904F271444Q28471948-ADFAA5B5-6804-4A37-97AB-D27C82AC7A16Q30436049-81A4EE98-D09F-4059-A8CA-601742E40D35Q30490247-69B77B9F-3FDC-49D7-A74E-FEFAC017051AQ33610075-ABA8D565-B75F-4319-93A5-C55E79F346C2Q33932460-2571B4D2-471D-4EA8-8269-B57CD113B2F8Q33947959-A0634C8A-A756-4411-9895-77342765A8DAQ34088424-288B4DB4-EE22-47C5-BC4A-80D43B7AF22FQ34496697-9DDB35B1-09F9-4AA8-9E17-1E0AEA2B07B0Q34497010-06BAF516-26FA-48FA-8C36-7B8461F27ACDQ34597750-BCD688A4-E9F5-447A-98E4-E5635C2897A6Q34852402-553DA889-8FDA-4413-AF89-A64BE86A6C65Q35050662-5A472BCA-F434-4709-A3B4-813E9056EDEBQ35208151-A6DF449B-DB8A-41EE-9F5C-7C7E3B193A02Q36014381-2E8B4397-91C0-4929-A001-6DD8F46F02D9Q36062442-D40F6536-9649-4D4B-8A76-6B65907612A4Q36210986-8D20D7E6-3CAF-47A8-88C3-647D040D7474Q36228534-66FBD326-AA74-4405-B5CD-EF23ACAB46E9Q36410371-7F1ACAB5-3DE6-40CB-8B68-3C9EED50E0FFQ36475391-0CC75A3A-35A4-4CA1-A660-29E18EFEC8B0Q36526959-460C9E8B-8B6E-4E3F-91D4-5BB2531CA6A2Q36582547-4C127097-82C9-4A67-8398-06EC2CFB9C7EQ36611021-56832A3B-3917-48D0-BA1E-1FA8F09B1F78Q36669662-33F0AFB8-7348-450E-9630-AFD88739C070Q36714384-893FA885-97B7-435B-8C13-260748783542Q36734936-845258DC-59DC-4D29-ACF3-AE1A2A0DCA0CQ36824808-C36055A8-AA6A-4EFE-9318-4F2EADA8A1E6Q36866617-597AF6F0-27E0-43FC-9B60-9F69444783FDQ36944441-1FAA0B19-4EB2-4B5E-90D5-0BBC6E19A615Q37004639-68BDA8E5-CF48-4F4D-AFC9-1337EBDFC67EQ37077239-42622531-439C-4A5C-A5EC-BA0A3ECB3B91Q37132640-BA7ACEAB-1F8B-4605-8555-C88D2A55E2DCQ37156381-3FCF0D34-ABB9-445F-8322-A9347AA4BBB0Q37235024-FD1ECBB7-ABBB-49D6-A7C9-E5B0D2907D76Q37235527-46F77142-7F5C-4C40-A615-F62ECEB8F703Q37263452-045422F0-D676-4231-B445-0C2201DF5C23
P2860
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@en
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@nl
type
label
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@en
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@nl
prefLabel
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@en
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@nl
P2093
P2860
P1476
Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.
@en
P2093
Brian W Brannigan
Daniel A Haber
Daphne W Bell
David Ferry
David P Ryan
David R Driscoll
Dennis C Sgroi
Eunice L Kwak
Gregory Y Lauwers
P2860
P304
P356
10.1158/1078-0432.CCR-06-0189
P407
P433
P577
2006-07-01T00:00:00Z